CA2830792A1 - Neuroprotective peptides - Google Patents

Neuroprotective peptides Download PDF

Info

Publication number
CA2830792A1
CA2830792A1 CA2830792A CA2830792A CA2830792A1 CA 2830792 A1 CA2830792 A1 CA 2830792A1 CA 2830792 A CA2830792 A CA 2830792A CA 2830792 A CA2830792 A CA 2830792A CA 2830792 A1 CA2830792 A1 CA 2830792A1
Authority
CA
Canada
Prior art keywords
amino acid
peptide
acid sequence
isolated peptide
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2830792A
Other languages
English (en)
French (fr)
Inventor
Elhanan Pinner
Nava Zisapel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of CA2830792A1 publication Critical patent/CA2830792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2830792A 2011-03-24 2012-03-22 Neuroprotective peptides Abandoned CA2830792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466966P 2011-03-24 2011-03-24
US61/466,966 2011-03-24
PCT/IL2012/050104 WO2012127475A1 (en) 2011-03-24 2012-03-22 Neuroprotective peptides

Publications (1)

Publication Number Publication Date
CA2830792A1 true CA2830792A1 (en) 2012-09-27

Family

ID=45999925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2830792A Abandoned CA2830792A1 (en) 2011-03-24 2012-03-22 Neuroprotective peptides

Country Status (13)

Country Link
US (1) US20140045764A1 (enExample)
EP (1) EP2688582B1 (enExample)
JP (1) JP5960793B2 (enExample)
KR (1) KR20140036164A (enExample)
CN (1) CN103648517B (enExample)
AU (1) AU2012232642B2 (enExample)
BR (1) BR112013024323A2 (enExample)
CA (1) CA2830792A1 (enExample)
EA (1) EA201391387A1 (enExample)
MX (1) MX2013010910A (enExample)
SG (1) SG193418A1 (enExample)
WO (1) WO2012127475A1 (enExample)
ZA (1) ZA201307169B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
EP3409130B1 (en) * 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
US10660934B2 (en) 2016-03-31 2020-05-26 Senju Pharmaceutical Co., Ltd. Neuroprotective peptide
EP3438120A4 (en) 2016-03-31 2019-12-04 Senju Pharmaceutical Co., Ltd. NEUROPROTECTIVE PEPTIDE
US12304932B2 (en) 2017-11-14 2025-05-20 Senju Pharmaceutical Co., Ltd. PACAP stabilized peptide
WO2020093172A1 (en) 2018-11-08 2020-05-14 Neovasc Tiara Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
US20250263459A1 (en) 2019-05-14 2025-08-21 Senju Pharmaceutical Co., Ltd. Stabilized pacap peptide
JPWO2020230869A1 (enExample) 2019-05-14 2020-11-19
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0703989B1 (en) * 1993-06-18 1997-11-05 Oy Biotie Therapies COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
CA2179391A1 (en) * 1994-01-18 1995-07-20 Edgar Haber Cd44 expression in smooth muscle cells
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
US6559287B1 (en) * 1998-01-24 2003-05-06 Bristol-Myers Squibb Co. Artificial proteoglycans
ATE468350T1 (de) * 2004-10-14 2010-06-15 Karlsruher Inst Technologie Peptidische verbindungen und deren ableitungen für die behandllung von menschlichen krankheiten durch hemmung der signalübertragung über wachstumfaktoren
CA2692861A1 (en) * 2007-07-10 2009-01-15 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases

Also Published As

Publication number Publication date
AU2012232642B2 (en) 2016-12-08
WO2012127475A1 (en) 2012-09-27
MX2013010910A (es) 2014-03-27
JP5960793B2 (ja) 2016-08-02
CN103648517A (zh) 2014-03-19
SG193418A1 (en) 2013-10-30
CN103648517B (zh) 2016-04-20
ZA201307169B (en) 2014-05-28
AU2012232642A1 (en) 2013-10-17
BR112013024323A2 (pt) 2017-06-13
KR20140036164A (ko) 2014-03-25
US20140045764A1 (en) 2014-02-13
EA201391387A1 (ru) 2014-01-30
EP2688582A1 (en) 2014-01-29
EP2688582B1 (en) 2017-02-15
JP2014510101A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
AU2012232642B2 (en) Neuroprotective peptides
US10040836B2 (en) Peptides for the treatment of neurodegenerative diseases
CA2773935C (en) Peptides for the treatment of oxidative stress related disorders
RU2762089C2 (ru) ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
US20250032580A1 (en) Use of adnf polypeptides in therapy
EP4137502A1 (en) Vipr2 antagonist peptide
JP7066409B2 (ja) 癌または転移性疾患の治療または予防における環状アセチルコリンエステラーゼｃ末端ペプチド
AU2019300567B2 (en) Peptide compounds and therapeutic uses of same
CN114375333B (zh) 包含赖氨酰氧化酶的前肽的组合物及其用途
US20220306710A1 (en) Treating alzheimer's disease
CA3052708A1 (en) Novel alpha conotoxin peptides
CN110520144B (zh) 肽激酶抑制剂及其使用方法
EP2989119B1 (en) Use of inhibitory peptides for the treatment of inflammatory diseases
WO2017132728A1 (en) Proteinaceous compounds and uses therefor
EP3116893B1 (en) A chimeric peptide that interacts with cell membrane gangliosides
EA051325B1 (ru) Пептидные соединения и их терапевтическое применение

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180322